Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Cash from Investing Activities (2017 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Cash from Investing Activities for 11 consecutive years, with $94673.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Cash from Investing Activities changed N/A year-over-year to $94673.0, compared with a TTM value of $94673.0 through Feb 2025, up 403.47%, and an annual FY2024 reading of $113477.0, up 359.38% over the prior year.
  • Cash from Investing Activities was $94673.0 for Q2 2024 at CNBX Pharmaceuticals, up from $20000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.1 million in Q3 2020 and bottomed at -$1196.0 in Q4 2023.
  • Average Cash from Investing Activities over 5 years is $298178.9, with a median of $25742.0 recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 233.92% in 2020, while the deepest fall reached 100.12% in 2020.
  • Year by year, Cash from Investing Activities stood at -$943.0 in 2020, then surged by 45.6% to -$513.0 in 2021, then soared by 5117.93% to $25742.0 in 2022, then plummeted by 104.65% to -$1196.0 in 2023, then soared by 8015.8% to $94673.0 in 2024.
  • Business Quant data shows Cash from Investing Activities for CNBX at $94673.0 in Q2 2024, $20000.0 in Q1 2024, and -$1196.0 in Q4 2023.